Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 124

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms

Lindemann, Antje, Patel, Ameeta A., Silver, Natalie L., Tang, Lin, Liu, Zhiyi, Wang, Li, Tanaka, Noriaki, Rao, Xiayu, Takahashi, Hideaki, Maduka, Nakachi K., Zhao, Mei, Chen, Tseng-Cheng, Liu, WeiWei, Gao, Meng, Wang, Jing, Frank, Steven J., Hittelman, Walter N., Mills, Gordon B., Myers, Jeffrey N., Osman, Abdullah A.·2019·Clinical Cancer Research

Abstract

Purpose: TP53 mutations are highly prevalent in head and neck squamous cell carcinoma (HNSCC) and associated with increased resistance to conventional treatment primarily consisting of chemotherapy and radiation. Restoration of wild-type p53 function in TP53-mutant cancer cells represents an attractive therapeutic approach and has been explored in recent years. In this study, the efficacy of a putative p53 reactivator called COTI-2 was evaluated in HNSCC cell lines with different TP53 status. Experimental Design: Clonogenic survival assays and an orthotopic mouse model of oral cancer were used to examine in vitro and in vivo sensitivity of HNSCC cell lines with either wild-type, null, or mutant TP53 to COTI-2 alone, and in combination with cisplatin and/or radiation. Western blotting, cell cycle, live-cell imaging, RNA sequencing, reverse-phase protein array, chromatin immunoprecipitation, and apoptosis analyses were performed to dissect molecular mechanisms. Results: COTI-2 decreased clonogenic survival of HNSCC cells and potentiated response to cisplatin and/or radiation in vitro and in vivo irrespective of TP53 status. Mechanistically, COTI-2 normalized wild-type p53 target gene expression and restored DNA-binding properties to the p53-mutant protein in HNSCC. In addition, COTI-2 induced DNA damage and replication stress responses leading to apoptosis and/or senescence. Furthermore, COTI-2 lead to activation of AMPK and inhibition of the mTOR pathways in vitro in HNSCC cells. Conclusions: COTI-2 inhibits tumor growth in vitro and in vivo in HNSCC likely through p53-dependent and p53-independent mechanisms. Combination of COTI-2 with cisplatin or radiation may be highly relevant in treating patients with HNSCC harboring TP53 mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-0096

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 28

  1. Adelstein, 2003, An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer, J Clin Oncol, 21, 92, 10.1200/JCO.2003.01.008 · DOI · Paper page
  2. Agrawal, 2011, Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1, Science, 333, 1154, 10.1126/science.1206923 · DOI · Paper page
  3. Pickering, 2013, Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers, Cancer Discov, 3, 770, 10.1158/2159-8290.CD-12-0537 · DOI · Paper page
  4. Cancer Genome Atlas Network, 2015, Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, 517, 576, 10.1038/nature14129 · DOI · Paper page
  5. Rivlin, 2015, p53 orchestrates between normal differentiation and cancer, Semin Cancer Biol, 32, 10, 10.1016/j.semcancer.2013.12.006 · DOI
  6. Osman, 2015, Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients, Cancer Res, 75, 1205, 10.1158/0008-5472.CAN-14-2729 · DOI
  7. Bykov, 2005, Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs, J Biol Chem, 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
  8. Yu, 2012, Allele-specific p53 mutant reactivation, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042 · DOI · Paper page
  9. Yu, 2014, Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism, Oncotarget, 5, 8879, 10.18632/oncotarget.2432 · DOI · Paper page
  10. Salim, 2016, COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo, Oncotarget, 7, 41363, 10.18632/oncotarget.9133 · DOI · Paper page
  11. Maleki, 2018, Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines, PLoS One, 13, e0191766, 10.1371/journal.pone.0191766 · DOI
  12. Westin, 2018, Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer [abstract], 10.1158/1538-7445.AM2018-CT033 · doi:10.1158/1538-7445.am2018-ct033
  13. Osman, 2015, Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence, Mol Cancer Ther, 14, 608, 10.1158/1535-7163.MCT-14-0735-T · DOI
  14. Chou, 2006, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol Rev, 58, 621, 10.1124/pr.58.3.10 · DOI · Paper page
  15. Tanaka, 2017, Synergistic antitumor activity of HDAC inhibitor vorinostat combined with WEE1 inhibitor AZD1775 in head and neck squamous cell carcinoma harboring high-risk TP53 mutation, Clin Cancer Res, 23, 6541, 10.1158/1078-0432.CCR-17-0947 · DOI
  16. Tanaka, 2018, Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1, Oncogene, 37, 1279, 10.1038/s41388-017-0032-z · DOI
  17. Tanaka, 2018, Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity, Oral Oncol, 87, 49, 10.1016/j.oraloncology.2018.10.018 · DOI
  18. Skinner, 2012, TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence, Clin Cancer Res, 18, 290, 10.1158/1078-0432.CCR-11-2260 · DOI · Paper page
  19. Chang, 2014, A comprehensive and high resolution genome-wide response of p53 to stress, Cell Rep, 8, 514, 10.1016/j.celrep.2014.06.030 · DOI
  20. Dohn, 2001, p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes, Oncogene, 20, 3193, 10.1038/sj.onc.1204427 · DOI · Paper page
  21. Byers, 2012, Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1, Cancer Discov, 2, 798, 10.1158/2159-8290.CD-12-0112 · DOI · Paper page
  22. Ribeiro-Rodrigues, 2017, Role of connexin 43 in different forms of intercellular communication–gap junctions, extracellular vesicles and tunnelling nanotubes, J Cell Sci, 130, 3619, 10.1242/jcs.200667 · DOI · Paper page
  23. El-Fouly, 1987, Scrape-loading and dye transfer, a rapid and simple technique to study gap junctional intracellular communication, Expt Cell Res, 168, 422, 10.1016/0014-4827(87)90014-0 · DOI · Paper page
  24. Babica, 2016, Scrape loading/dye transfer assay, Methods Mol Biol, 1437, 133, 10.1007/978-1-4939-3664-9_9 · doi:10.1007/978-1-4939-3664-9_9
  25. Azzam, 2001, Direct evidence for the participation of gap junction mediated intercellular communication in the transmission of damage signals from a-particle irradiated to nonirradiated cells, PNAS, 98, 473
  26. Lindemann, 2018, Targeting the DNA damage response in OSCC with TP53 mutations, J Dent Res, 97, 635, 10.1177/0022034518759068 · DOI · Paper page
  27. Fitzgerald, 2015, Reactive oxygen species and p21Waf1/Cip1 are both essential for p52-mediated senescence of head and neck cancer cells, Cell Death Dis, 6, e1678, 10.1038/cddis.2015.44 · DOI
  28. Jeon, 2016, Regulation and function of AMPK in physiology and diseases, Exp Mol Med, 48, e245, 10.1038/emm.2016.81 · DOI · Paper page

Cited by

See all 124

Metadata

Authors
Lindemann, A., Patel, A. A., Silver, N. L., Tang, L., Liu, Z., Wang, L., Tanaka, N., Rao, X., Takahashi, H., Maduka, N. K., Zhao, M., Chen, T.-C., Liu, W., Gao, M., Wang, J., Frank, S. J., Hittelman, W. N., Mills, G. B., Myers, J. N., & Osman, A. A.
Venue
Clinical Cancer Research
Published
2019-09-13
Volume
25
Issue
18
Pages
5650-5662
ISSN
  • 1078-0432
  • 1557-3265
Cited by
124
References
2
Language
en
Funders
  • NIH/NIDCR (R01DE024601)
  • MD Anderson's Cancer Center (P30CA016672)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0096
The paper
Lindemann, A., Patel, A. A., Silver, N. L., Tang, L., Liu, Z., Wang, L., Tanaka, N., Rao, X., Takahashi, H., Maduka, N. K., Zhao, M., Chen, T.-C., Liu, W., Gao, M., Wang, J., Frank, S. J., Hittelman, W. N., Mills, G. B., Myers, J. N., & Osman, A. A. (2019). COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0096

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.